×
About 1,850 results

ALLMedicine™ Tardive Dyskinesia Center

Research & Reviews  469 results

Aim to Reduce Movements in Tardive Dyskinesia
https://clinicaltrials.gov/ct2/show/NCT02195700

Nov 9th, 2021 - The purpose of this study is to determine whether an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia.

Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)
https://clinicaltrials.gov/ct2/show/NCT03202303

Nov 8th, 2021 - There is a clear unmet need for new therapeutics to treat irritability in children with ASD that do not have the metabolic and weight adverse event profiles of the currently approved treatments. Cannabidivarin (CBDV) is a nonpsychoactive phytocann...

Challenges in Treating Patients with Tardive Dyskinesia
https://www.mdedge.com/TD
Greg Mattingly, MD & Manish Jha et. al.

Nov 1st, 2021 - In this supplement to Current Psychiatry, Greg Mattingly, MD and Manish K. Jha, MBBS review dilemmas and treatment options for patients with tardive dyskinesia.

Resveratrol prevents haloperidol-induced mitochondria dysfunction through the induction...
https://doi.org/10.1016/j.neuro.2021.10.007
Neurotoxicology Hu M, Wang R et. al.

Oct 25th, 2021 - Haloperidol is a commonly used antipsychotic drug and may increase neuronal oxidative stress associated with the side effects, including tardive dyskinesia and neurite withdraw. Autophagy plays a protective role in response to the accumulated reac...

Efficacy and Safety of Fixed-Dose Deutetrabenazine in Children and Adolescents for Tics...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524312
JAMA Network Open; Coffey B, Jankovic J et. al.

Oct 19th, 2021 - Tourette syndrome is a neurodevelopmental disorder characterized by childhood onset of motor and phonic tics, often accompanied by behavioral and psychiatric comorbidities. Deutetrabenazine is a vesicular monoamine transporter 2 inhibitor approved...

see more →

Guidelines  1 results

Revisiting the Abnormal Involuntary Movement Scale: Proceedings From the Tardive Dyskin...
https://doi.org/10.4088/JCP.17cs11959
The Journal of Clinical Psychiatry; Kane JM, Correll CU et. al.

May 10th, 2018 - To provide an historic overview of the Abnormal Involuntary Movement Scale (AIMS) in clinical trials of tardive dyskinesia (TD), with current recommendations for analyzing and interpreting AIMS data. Seven psychiatrists and 1 neurologist were sele...

see more →

Drugs  141 results see all →

Clinicaltrials.gov  27 results

Aim to Reduce Movements in Tardive Dyskinesia
https://clinicaltrials.gov/ct2/show/NCT02195700

Nov 9th, 2021 - The purpose of this study is to determine whether an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia.

Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)
https://clinicaltrials.gov/ct2/show/NCT03202303

Nov 8th, 2021 - There is a clear unmet need for new therapeutics to treat irritability in children with ASD that do not have the metabolic and weight adverse event profiles of the currently approved treatments. Cannabidivarin (CBDV) is a nonpsychoactive phytocann...

Transpyloric Stenting as a Predictor for G-POEM for Refractory Gastroparesis
https://clinicaltrials.gov/ct2/show/NCT04287647

Oct 4th, 2021 - Gastroparesis is defined as a complex syndrome of symptoms including early satiety, post-prandial fullness, nausea, vomiting, bloating, and upper abdominal pain with a corresponding objective delay in gastric emptying in the absence of mechanical ...

Treatment of Psychosis and Agitation in Alzheimer's Disease
https://clinicaltrials.gov/ct2/show/NCT02129348

Aug 16th, 2021 - Symptoms of psychosis or agitation are common in Alzheimer's disease. These symptoms are associated with distress for the patient, an increased burden for caregivers, more rapid cognitive decline, greater risk of institutionalization and mortality...

Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia
https://clinicaltrials.gov/ct2/show/NCT00917293

Feb 15th, 2019 - This study will assess the effect of Pyridoxal 5'-Phosphate on the reduction of expressed symptoms of moderate to severe tardive dyskinesia in patients with schizophrenia and schizoaffective disorders who are on a stable dose, and regime, of eithe...

see more →

News  101 results

Challenges in Treating Patients with Tardive Dyskinesia
https://www.mdedge.com/TD
Greg Mattingly, MD & Manish Jha et. al.

Nov 1st, 2021 - In this supplement to Current Psychiatry, Greg Mattingly, MD and Manish K. Jha, MBBS review dilemmas and treatment options for patients with tardive dyskinesia.

Optimal Antipsychotic Dose for Schizophrenia Relapse Identified
https://www.medscape.com/viewarticle/958348

Sep 8th, 2021 - Dr Stefan Leucht A middle-of-the-road dose of an antipsychotic appears to be optimal for relapse prevention in stable schizophrenia, new research suggests. Results of a meta-analysis show a 5-mg/day equivalent risperidone dose worked best. Higher ...

Guidance Provided for Telepsychiatry in Tardive Dyskinesia
https://www.medscape.com/viewarticle/953795

Jun 25th, 2021 - Tardive dyskinesia (TD) can be reasonably managed through telemedicine, but it should be employed as part of a hybrid strategy that ideally includes an office visit at the time of diagnosis and yearly intervals thereafter, according to an expert w...

Fast Five Quiz: How Much Do You Know About Tardive Dyskinesia?
https://reference.medscape.com/viewarticle/910550

May 21st, 2021 - Tardive dyskinesia (TD) is a movement disorder caused by the use of dopaminergic antagonists or other antipsychotic medications. Patients with schizophrenia, schizoaffective disorder, or bipolar disorder who have a history of long-term use of dopa...

Fast Five Quiz: How Much Do You Know About Tardive Dyskinesia?
https://www.medscape.com/viewarticle/910550

May 21st, 2021 - Tardive dyskinesia (TD) is a movement disorder caused by the use of dopaminergic antagonists or other antipsychotic medications. Patients with schizophrenia, schizoaffective disorder, or bipolar disorder who have a history of long-term use of dopa...

see more →

Patient Education  1 results see all →